TELA Bio (TELA Bio) ROCE %

: -69.41% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TELA Bio's annualized ROCE % for the quarter that ended in Dec. 2023 was -69.41%.

TELA Bio ROCE % Historical Data

The historical data trend for TELA Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-47.71

-35.77

-45.03

-74.93

-71.12

TELA Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-58.80	-86.39	-60.40	-50.21	-69.41

TELA Bio ROCE % Calculation

TELA Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-41.441	/	( ( (67.855 - 12.403)	+	(78.048 - 16.967) )	/ 2 )
	=	-41.441	/	( (55.452	+	61.081)	/ 2 )
	=	-41.441	/	58.2665
	=	-71.12 %

TELA Bio's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-46.18	/	( ( (87.317 - 15.334)	+	(78.048 - 16.967) )	/ 2 )
	=	-46.18	/	( ( 71.983	+	61.081 )	/ 2 )
	=	-46.18	/	66.532
	=	-69.41 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

TELA Bio (NAS:TELA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TELA Bio ROCE % Related Terms

Thank you for viewing the detailed overview of TELA Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TELA Bio (TELA Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355

Website

https://www.telabio.com

TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

Executives

Gregory A. Firestone	officer: Chief Business Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca	officer: COO and CFO	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish	director, officer: Chief Executive Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p.	other: See footnotes 1 and 2	280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp	10 percent owner	QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p.	10 percent owner	CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran	director	0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess	director	2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans	director	1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355